Figure 3. Treatment response to evofosfamide and single high-dose irradiation in vivo.

Tumor growth delay of A549-derived xenografts in immunocompromised mice in response to combined treatment with evofosfamide (50 mg/kg, Q3Dx5) and single high-dose IR (1×10 Gy). Control mice were treated i.p. with saline. (A) Neoadjuvant (left panel), concomitant (middle panel), and adjuvant (right panel) regimens are shown. Neoadjuvant (left panel), with evofosfamide given on days 1-12 followed by irradiation; concomitant (middle panel), with evofosfamide given on days 1-12 and IR on day 6; adjuvant (right panel), IR given on day 0 followed by treatment with evofosfamide. 7-14 mice per treatment groups were used. Error bars represent SEM. (B) Kaplan-Meier curves for tumors reaching 600mm³ tumor volume.